Skip to main content

Current and Novel Psychopharmacological Drugs for Anxiety Disorders

Part of the Advances in Experimental Medicine and Biology book series (AEMB,volume 1191)

Abstract

Anxiety disorders, including panic disorder/agoraphobia (PDA), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and others, are the most prevalent mental disorders. In this paper, recommendations are given for the psychopharmacological treatment of these disorders which are based on comprehensive treatment guidelines, meta-analyses, and systematic reviews of available randomized controlled studies. Anxiety disorders can effectively be treated with psychotherapy, pharmacotherapy, or a combination of both. First-line drugs are the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Benzodiazepines are not recommended for routine use due to their possible addiction potential. Other treatment options include the calcium modulator pregabalin, tricyclic antidepressants, buspirone, moclobemide, and others. Drug treatment can be combined with psychological treatments. Novel treatment strategies include medications that act on GABA, glutamate, and other neurotransmitter systems. After remission, medications should be continued for 6 to 12 months.

Keywords

  • Panic disorder
  • Generalized anxiety disorder
  • Social anxiety disorder
  • Separation anxiety disorder
  • Selective mutism
  • Treatment
  • Psychotherapy
  • Drug treatment

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-981-32-9705-0_19
  • Chapter length: 19 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   149.00
Price excludes VAT (USA)
  • ISBN: 978-981-32-9705-0
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   199.99
Price excludes VAT (USA)
Hardcover Book
USD   199.99
Price excludes VAT (USA)

References

  1. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327–35. Epub 2015/10/22

    PubMed  PubMed Central  Google Scholar 

  2. Bandelow B, Reitt M, Rover C, Michaelis S, Gorlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30(4):183–92. Epub 2015/05/02

    PubMed  CrossRef  Google Scholar 

  3. Bandelow B, Baldwin D, Abelli M, Altamura C, Dell’Osso B, Domschke K, et al. Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics. World J Biol Psychiatry. 2016;17(5):321–65. Epub 2016/07/13

    PubMed  CrossRef  Google Scholar 

  4. Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, Bourin M, Chamberlain SR, et al. Biological markers for anxiety disorders, OCD and PTSD: a consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry. 2017;18(3):162–214. Epub 2016/07/16

    PubMed  CrossRef  Google Scholar 

  5. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50(2):85–94.

    CAS  PubMed  CrossRef  Google Scholar 

  6. Alonso J, Lepine JP, Committee ESMS. Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD). J Clin Psychiatry. 2007;68(Suppl 2):3–9.

    PubMed  Google Scholar 

  7. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77–84. Epub 2012/05/01

    CAS  PubMed  CrossRef  Google Scholar 

  8. Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403–39. Epub 2014/04/10

    PubMed  CrossRef  CAS  Google Scholar 

  9. Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel ME. The German guidelines for the treatment of anxiety disorders. Eur Arch Psychiatry Clin Neurosci. 2015;265(5):363–73. Epub 2014/11/19

    PubMed  CrossRef  Google Scholar 

  10. Benjamin J, Ben-Zion IZ, Karbofsky E, Dannon P. Double-blind placebo-controlled pilot study of paroxetine for specific phobia. Psychopharmacology. 2000;149(2):194–6. Epub 2000/05/11

    CAS  PubMed  CrossRef  Google Scholar 

  11. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–58.

    CAS  PubMed  CrossRef  Google Scholar 

  12. Muscatello MR, Spina E, Bandelow B, Baldwin DS. Clinically relevant drug interactions in anxiety disorders. Hum Psychopharmacol. 2012;27(3):239–53. Epub 2012/02/09

    CAS  PubMed  CrossRef  Google Scholar 

  13. Stahl MMS, Lindquist M, Pettersson M, Edwards IR, Sanderson JH, Taylor NFA, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol. 1997;53(3–4):163–9.

    CAS  PubMed  CrossRef  Google Scholar 

  14. Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013;9:883–92.

    CAS  PubMed  PubMed Central  CrossRef  Google Scholar 

  15. Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev. 2005;24(3):205–14.

    CAS  PubMed  CrossRef  Google Scholar 

  16. Stahl SM. Don’t ask, don’t tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry. 2002;63(9):756–7.

    PubMed  CrossRef  Google Scholar 

  17. Starcevic V. The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. Expert Rev Neurother. 2014;14(11):1275–86.

    CAS  PubMed  CrossRef  Google Scholar 

  18. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry. 1990;47(10):908–15.

    CAS  PubMed  CrossRef  Google Scholar 

  19. Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation [published erratum appears in Arch Gen Psychiatry 1991; 48(1):51]. Arch Gen Psychiatry. 1990;47(10):899–907.

    CAS  PubMed  CrossRef  Google Scholar 

  20. Smith DE, Landry MJ. Benzodiazepine dependency discontinuation: focus on the chemical dependency detoxification setting and benzodiazepine-polydrug abuse. J Psychiatr Res. 1990;24(Suppl 2):145–56. Epub 1990/01/01

    PubMed  CrossRef  Google Scholar 

  21. Bradwejn J. Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: clinical issues and future directions. Can J Psychiatry. 1993;38(Suppl 4):S109–13. Epub 1993/11/01

    PubMed  Google Scholar 

  22. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. New Engl J Med. 1993;13:1398–405.

    Google Scholar 

  23. Livingston MG. Benzodiazepine dependence. Br J Hosp Med. 1994;51(6):281–6. Epub 1994/03/05

    CAS  PubMed  Google Scholar 

  24. Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Can J Clin Pharmacol. 1999;6(2):69–83. Epub 1999/10/16

    CAS  PubMed  Google Scholar 

  25. Schweizer E, Rickels K, De Martinis N, Case G, Garcia-Espana F. The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients. Psychol Med. 1998;28(3):713–20. Epub 1998/06/17

    CAS  PubMed  CrossRef  Google Scholar 

  26. Rickels K. Benzodiazepines in the treatment of anxiety. Am J Psychother. 1982;36(3):358–70. Epub 1982/07/01

    CAS  PubMed  CrossRef  Google Scholar 

  27. Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel ME. The diagnosis of and treatment recommendations for anxiety disorders. Deutsch Arztebl Int. 2014;111(27–28):473–80. Epub 2014/08/21

    Google Scholar 

  28. Berney P, Halperin D, Tango R, Daeniker-Dayer I, Schulz P. A major change of prescribing pattern in absence of adequate evidence: benzodiazepines versus newer antidepressants in anxiety disorders. Psychopharmacol Bull. 2008;41(3):39–47.

    PubMed  Google Scholar 

  29. Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry. 2001;58(7):681–6. Epub 2001/07/31

    CAS  PubMed  CrossRef  Google Scholar 

  30. Otto MW, Pollack MH, Sachs GS, Reiter SR, Meltzer-Brody S, Rosenbaum JF. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry. 1993;150(10):1485–90. Epub 1993/10/01

    CAS  PubMed  CrossRef  Google Scholar 

  31. Spiegel DA. Psychological strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol. 1999;19(6 Suppl 2):17S–22S. Epub 1999/12/10

    CAS  PubMed  CrossRef  Google Scholar 

  32. Möller HJ, Volz HP, Reimann IW, Stoll KD. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol. 2001;21(1):59–65. Epub 2001/02/24

    PubMed  CrossRef  Google Scholar 

  33. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(5):561–6. Epub 2008/09/17

    CAS  PubMed  CrossRef  Google Scholar 

  34. Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry. 2012;73(7):1002–8. Epub 2012/08/21

    CAS  PubMed  CrossRef  Google Scholar 

  35. Stein DJ, Ahokas A, Marquez MS, Hoschl C, Oh KS, Jarema M, et al. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. J Clin Psychiatry. 2014;75(4):362–8.

    CAS  PubMed  CrossRef  Google Scholar 

  36. Stein DJ, Ahokas A, Jarema M, Avedisova AS, Vavrusova L, Chaban O, et al. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: a 12-week, double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2017;27(5):526–37.

    CAS  PubMed  CrossRef  Google Scholar 

  37. Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 2019. Epub 2019/02/05.

    Google Scholar 

  38. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2010;13(3):305–20. Epub 2009/08/21

    CAS  PubMed  CrossRef  Google Scholar 

  39. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011;31(4):418–28. Epub 2011/06/23

    CAS  PubMed  CrossRef  Google Scholar 

  40. Gommoll C, Durgam S, Mathews M, Forero G, Nunez R, Tang X, et al. A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder. Depress Anxiety. 2015;32(6):451–9.

    CAS  PubMed  PubMed Central  CrossRef  Google Scholar 

  41. Gommoll C, Forero G, Mathews M, Nunez R, Tang X, Durgam S, et al. Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study. Int Clin Psychopharmacol. 2015;30(6):297–306.

    PubMed  PubMed Central  CrossRef  Google Scholar 

  42. Careri JM, Draine AE, Hanover R, Liebowitz MR. A 12-week double-blind, placebo-controlled, flexible-dose trial of vilazodone in generalized social anxiety disorder. Prim Care Companion CNS Disord. 2015;17(6)

    Google Scholar 

  43. Bandelow B. Wedekind D. Lancet: Network analyses to rank pharmacological treatments for generalised anxiety disorder; 2019. Epub 2019/02/05

    Google Scholar 

  44. Baldwin DS, Stein DJ, Dolberg OT, Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol. 2009;24(4):269–75. Epub 2009/04/01

    CAS  PubMed  CrossRef  Google Scholar 

  45. Yoshinaga N, Matsuki S, Niitsu T, Sato Y, Tanaka M, Ibuki H, et al. Cognitive behavioral therapy for patients with social anxiety disorder who remain symptomatic following antidepressant treatment: a randomized, assessor-blinded, controlled trial. Psychother Psychosom. 2016;85(4):208–17.

    PubMed  CrossRef  Google Scholar 

  46. Campbell-Sills L, Roy-Byrne PP, Craske MG, Bystritsky A, Sullivan G, Stein MB. Improving outcomes for patients with medication-resistant anxiety: effects of collaborative care with cognitive behavioral therapy. Depress Anxiety. 2016;

    Google Scholar 

  47. Bandelow B, Schuller K. Mean age and gender distribution of patients with major mental disorders participating in clinical trials. Eur Arch Psychiatry Clin Neurosci. 2019. Epub 2019/01/03

    Google Scholar 

  48. Hussain FS, Dobson ET, Strawn JR. Pharmacologic treatment of pediatric anxiety disorders. Curr Treat Options Psychiatry. 2016;3(2):151–60.

    PubMed  PubMed Central  CrossRef  Google Scholar 

  49. Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359(26):2753–66.

    CAS  PubMed  PubMed Central  CrossRef  Google Scholar 

  50. Klein RG, Koplewicz HS, Kanner A. Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry. 1992;31(1):21–8. Epub 1992/01/01

    CAS  PubMed  CrossRef  Google Scholar 

  51. Gittelman-Klein R, Klein DF. School phobia: controlled imipramine treatment. Calif Med. 1971;115(3):42. Epub 1971/09/01

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Bernstein GA, Garfinkel BD, Borchardt CM. Comparative studies of pharmacotherapy for school refusal. J Am Acad Child Adolesc Psychiatry. 1990;29(5):773–81. Epub 1990/09/01

    CAS  PubMed  CrossRef  Google Scholar 

  53. Bernstein GA, Borchardt CM, Perwien AR, Crosby RD, Kushner MG, Thuras PD, et al. Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry. 2000;39(3):276–83. Epub 2000/03/14

    CAS  PubMed  CrossRef  Google Scholar 

  54. Berney T, Kolvin I, Bhate SR, Garside RF, Jeans J, Kay B, et al. School phobia: a therapeutic trial with clomipramine and short-term outcome. Br J Psychiatry. 1981;138:110–8. Epub 1981/02/01

    CAS  PubMed  CrossRef  Google Scholar 

  55. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs): use and safety [database on the Internet]. Medicines & Healthcare products Regulatory Agency (MHRA). 2014 [cited 18/05/2017]. Available from: https://www.gov.uk/government/publications/ssris-and-snris-use-and-safety/selective-serotonin-reuptake-inhibitors-ssris-and-serotonin-and-noradrenaline-reuptake-inhibitors-snris-use-and-safety

  56. Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2012;11:CD004851.

    PubMed  Google Scholar 

  57. Libby AM, Brent DA, Morrato EH, Orton HD, Allen R, Valuck RJ. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry. 2007;164(6):884–91.

    PubMed  CrossRef  Google Scholar 

  58. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007;164(9):1356–63. Epub 2007/08/31

    PubMed  CrossRef  Google Scholar 

  59. Schneier FR, Moskow DM, Choo TH, Galfalvy H, Campeas R, Sanchez-Lacay A. A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder. Depress Anxiety. 2017;34(12):1085–95. Epub 2017/10/27

    CAS  PubMed  CrossRef  Google Scholar 

  60. Bergman RL, Gonzalez A, Piacentini J, Keller ML. Integrated behavior therapy for selective mutism: a randomized controlled pilot study. Behav Res Ther. 2013;51(10):680–9.

    PubMed  CrossRef  Google Scholar 

  61. Oerbeck B, Stein MB, Wentzel-Larsen T, Langsrud O, Kristensen H. A randomized controlled trial of a home and school-based intervention for selective mutism – defocused communication and behavioural techniques. Child Adolesc Mental Health. 2014;19(3):192–8.

    Google Scholar 

  62. Manassis K, Oerbeck B, Overgaard KR. The use of medication in selective mutism: a systematic review. Eur Child Adolesc Psychiatry. 2016;25(6):571–8.

    PubMed  CrossRef  Google Scholar 

  63. Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397–407.

    CAS  PubMed  PubMed Central  CrossRef  Google Scholar 

  64. Oyebode F, Rastogi A, Berrisford G, Coccia F. Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther. 2012;135(1):71–7. Epub 2012/04/10

    CAS  PubMed  CrossRef  Google Scholar 

  65. Muzik M, Hamilton SE. Use of antidepressants during pregnancy?: what to consider when weighing treatment with antidepressants against untreated depression. Matern Child Health J. 2016;20(11):2268–79.

    PubMed  CrossRef  Google Scholar 

  66. Patterson B, Boyle MH, Kivlenieks M, Van Ameringen M. The use of waitlists as control conditions in anxiety disorders research. J Psychiatr Res. 2016;83:112–20.

    PubMed  CrossRef  Google Scholar 

  67. James AC, James G, Cowdrey FA, Soler A, Choke A. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2015;2:CD004690.

    Google Scholar 

  68. Bandelow B, Sagebiel A, Belz M, Gorlich Y, Michaelis S, Wedekind D. Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Br J Psychiatry. 2018;212(6):333–8. Epub 2018/05/01

    PubMed  CrossRef  Google Scholar 

  69. Akbar S, Subhan F, Karim N, Aman U, Ullah S, Shahid M, et al. Characterization of 6-methoxyflavanone as a novel anxiolytic agent: a behavioral and pharmacokinetic approach. Eur J Pharmacol. 2017;801:19–27. Epub 2017/03/05

    CAS  PubMed  CrossRef  Google Scholar 

  70. Kalinichev M, Girard F, Haddouk H, Rouillier M, Riguet E, Royer-Urios I, et al. The drug candidate, ADX71441, is a novel, potent and selective positive allosteric modulator of the GABAB receptor with a potential for treatment of anxiety, pain and spasticity. Neuropharmacology. 2017;114:34–47. Epub 2016/11/28

    CAS  PubMed  CrossRef  Google Scholar 

  71. Salat K, Podkowa A, Malikowska N, Kern F, Pabel J, Wojcieszak E, et al. Novel, highly potent and in vivo active inhibitor of GABA transporter subtype 1 with anticonvulsant, anxiolytic, antidepressant and antinociceptive properties. Neuropharmacology. 2017;113(Pt A):331–42. Epub 2016/11/05

    CAS  PubMed  CrossRef  Google Scholar 

  72. Rupprecht R, Rammes G, Eser D, Baghai TC, Schule C, Nothdurfter C, et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science. 2009;325(5939):490–3.

    CAS  PubMed  CrossRef  Google Scholar 

  73. Wang DS, Han J, Li S, Sun T, Guo YY, Kang WB, et al. Antidepressant-like and anxiolytic-like effects of ZBD-2, a novel ligand for the translocator protein (18 kDa). Neuromolecular Med. 2017;19(1):57–68. Epub 2016/08/22

    PubMed  CrossRef  CAS  Google Scholar 

  74. Simen A, Whitlock M, Qiu R, Miceli J, Zumpano L, Du Metz M, et al. An 8-week, randomized, phase 2, double-blind, sequential parallel-group comparison study of two dose levels of the GABAA positive allosteric modulator PF-06372865 compared with placebo as an adjunctive treatment in outpatients with inadequate response to standard of care for generalized anxiety disorder. J Clin Psychopharmacol. 2019;39(1):20–7. Epub 2018/12/12

    CAS  PubMed  CrossRef  Google Scholar 

  75. Swanson CJ, Bures M, Johnson MP, Linden A-M, Monn JA, Schoepp DD. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov. 2005;4:131.

    CAS  PubMed  CrossRef  Google Scholar 

  76. Ferraguti F. Metabotropic glutamate receptors as targets for novel anxiolytics. Curr Opin Pharmacol. 2018;38:37–42. Epub 2018/03/02

    CAS  PubMed  CrossRef  Google Scholar 

  77. Montes GC, da Silva BNM, Rezende B, Sudo RT, Ferreira VF, de Carvalho da Silva F, et al. The hypnotic, anxiolytic, and antinociceptive profile of a novel micro-opioid agonist. Molecules. 2017;22(5):800. Epub 2017/05/17

    PubMed Central  CrossRef  CAS  Google Scholar 

  78. Patel S, Hill MN, Cheer JF, Wotjak CT, Holmes A. The endocannabinoid system as a target for novel anxiolytic drugs. Neurosci Biobehav Rev. 2017;76(Pt A):56–66. Epub 2017/04/25

    CAS  PubMed  PubMed Central  CrossRef  Google Scholar 

  79. Shi QX, Yang LK, Shi WL, Wang L, Zhou SM, Guan SY, et al. The novel cannabinoid receptor GPR55 mediates anxiolytic-like effects in the medial orbital cortex of mice with acute stress. Mol Brain. 2017;10(1):38. Epub 2017/08/13

    PubMed  PubMed Central  CrossRef  CAS  Google Scholar 

  80. Baldwin DS, Hou R, Gordon R, Huneke NT, Garner M. Pharmacotherapy in generalized anxiety disorder: novel experimental medicine models and emerging drug targets. CNS Drugs. 2017;31(4):307–17. Epub 2017/03/18

    CAS  PubMed  CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Borwin Bandelow .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Bandelow, B. (2020). Current and Novel Psychopharmacological Drugs for Anxiety Disorders. In: Kim, YK. (eds) Anxiety Disorders. Advances in Experimental Medicine and Biology, vol 1191. Springer, Singapore. https://doi.org/10.1007/978-981-32-9705-0_19

Download citation